You are here:  Home     October 23, 2014


National Pediatric Sleep Groups   
News and activities from Pediatric Sleep Groups all over the world

Pediatric Sleep


IPSA suggestions   
help us to make IPSA more complete and useful, send information about pediatric sleep activities in Your country.

IPSA Congress 2014 - Porto Alegre - Brazil - Sunday, September 29, 2013

It is my pleasure to present the
III Congress of the International Pediatric Sleep Association (IPSA) - Porto Alegre (Brazil) 3-5 December 2014.

The importance of sleep for health, learning and psychomotor development in infancy, childhood and adolescence has been emphasized in the pediatric research in the last two decades and it has become more and more evident that ensuring a good sleep during development is of key importance for a later healthy life.
The IPSA Congress is an influential forum for sleep practitioners from around the world to network and exchange views, whilst learning from world-class researchers about the latest scientific and clinical developments in the field.
The success of the last two Congresses in Rome 2010 and Manchester 2012 has highlighted the magnitude of Pediatric Sleep Medicine in the scientific community and we hope that the 2014 Congress will provide a perfect balance between didactic and practical needs, in order to provide the technical knowhow and up-to-date knowledge that will enable participants to improve their practice.
As traditional for IPSA, the most renowned International opinion leaders in the field of Pediatric Sleep Medicine speakers will join the Congress and will highlight the recent significant advances in both basic science and clinical sleep medicine during development.
I hope that the world paediatric sleep community will gather together in the lively city of Porto Alegre to celebrate the best clinical practice and the latest advances in Pediatric Sleep Medicine.

Oliviero Bruni
President of the International Pediatric Sleep Association


IPSA Congress 5-7 december 2012 - Manchester City (UK)

IPSA Congress 5-7th December 2012 - Manchester (UK)  


IPSA 2010 - Abstract Book




Guia SAOS Infantil Espanola

New guidelines on the diagnosis and treatment of OSA in children published by the Spanish Pediatric Sleep Group. (available only in Spanish)



[PageLinks]     TIP: Press shift while clicking on the article to open in a new window.

Supraglottoplasty outcomes in neurologically affected and syndromic children.
Related Articles

Supraglottoplasty outcomes in neurologically affected and syndromic children.

JAMA Otolaryngol Head Neck Surg. 2014 Aug;140(8):704-11

Authors: Durvasula VS, Lawson BR, Bower CM, Richter GT

IMPORTANCE: Supraglottoplasty (SGP) failure is frequently attributed to coexistent medical comorbidities, but studies specifically evaluating outcomes in these populations are lacking.
OBJECTIVE: To assess SGP outcomes in patients with neurologic and syndromic comorbidities and severe laryngomalacia (LM).
DESIGN, SETTING, AND PARTICIPANTS: Case series with retrospective review of medical records of 54 patients with neurologic and/or syndromic comorbidity and severe LM who underwent SGP between 2004 and 2012 at a tertiary care pediatric institution.
INTERVENTIONS: Patients presented with severe LM that required SGP. Supraglottoplasty failure necessitated revision SGP, tracheostomy, or gastrostomy tube insertion, or LM and obstructive sleep apnea that required assisted ventilation (continuous positive airway pressure and bilevel positive airway pressure).
MAIN OUTCOMES AND MEASURES: Medical records were reviewed with a focus on patient factors, surgical timing, complications, and surgical and dysphagia outcomes. Patients were grouped based on their age at the time of SGP as infants (aged ≤12 months) and children (aged >12 months). Statistical comparisons were performed with SGP outcomes of infants with LM and no comorbidities.
RESULTS: Fifty-four patients met the inclusion criteria. Thirty-one (13 infants, 18 children) had a neurologic condition and 23 (15 infants, 8 children) had syndromes. The overall success rate of SGP was 67% (36 of 54) in these populations. Neurologic (P = .003) and syndromic (P < .001) comorbidities were associated with significant reduction in SGP success rates vs no comorbidities. Among SGP failures (18 of 54 [33%]), 13% (7 of 54) required tracheostomy, 9% (5 of 54) needed assisted ventilation, 7% (4 of 54) required a postoperative gastrostomy tube, and 4% (2 of 54) required revision SGP. In the neurologic comorbidities group, patients with cerebral palsy had significantly higher tracheostomy rates compared with those who had other neurologic pathologies constituting comorbidities (2 of 11 [18%] vs 0 of 20; P = .049). In infants, acute airway obstruction was the most common indication for SGP in the neurologically comorbidity and syndrome populations (success rates, 69% and 67%, respectively). In children, obstructive sleep apnea was the most common indication for SGP in the neurologic comorbidity and syndrome populations (success rates, 78% and 50%, respectively).
CONCLUSIONS AND RELEVANCE: Supraglottoplasty remains useful and outcomes were better in patients with neurologic comorbidity than in patients with syndromic comorbidity.

PMID: 25073682 [PubMed - indexed for MEDLINE]

A girl with tuberous sclerosis complex presenting with severe epilepsy and electrical status epilepticus during sleep, and with high-functioning autism and mutism.
Related Articles

A girl with tuberous sclerosis complex presenting with severe epilepsy and electrical status epilepticus during sleep, and with high-functioning autism and mutism.

Cogn Behav Neurol. 2014 Jun;27(2):88-95

Authors: Pacheva I, Panov G, Gillberg C, Neville B

Most patients with tuberous sclerosis complex (TSC) suffer from epilepsy, and many have cognitive and behavioral problems like severe intellectual disability, autism, and hyperactivity. Only rare patients with TSC and autism have a normal intelligence quotient. We report a 13-year-old girl with definite TSC who had early-onset severe epilepsy, autistic behavior, and moderate developmental delay. By school age, however, she had normal intelligence; her intelligence quotient was at least 70 based on a Stanford-Binet test that she refused to complete. She showed good reading, writing, and language comprehension skills, and the special abilities of hyperlexia, hypermnesia, and hypercalculia. However, she did not speak. Criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, and her Childhood Autism Rating Scale score of 36 indicated mild to moderate autism. She had severe electroencephalographic abnormalities: hypsarrhythmia, multifocal or generalized epileptiform discharges, and electrical status epilepticus during sleep, with a continuous left temporal focus. Magnetic resonance imaging showed many cortical tubers in all brain lobes, and subependymal nodules. We discuss possible explanations for her lack of speech. Considered as speech apraxia, her mutism could be either a symptom of her TSC or a component of her autism. Another possibility is that long-lasting electrical status epilepticus during sleep led to her autistic behavior and language arrest. Still another possibility is that a disinhibited mammalian target of rapamycin (mTOR) pathway was at the root of all of her neuropsychiatric symptoms.

PMID: 24968009 [PubMed - indexed for MEDLINE]

Effect of topical sucralfate vs clindamycin on posttonsillectomy pain in children aged 6 to 12 years: a triple-blind randomized clinical trial.
Related Articles

Effect of topical sucralfate vs clindamycin on posttonsillectomy pain in children aged 6 to 12 years: a triple-blind randomized clinical trial.

JAMA Otolaryngol Head Neck Surg. 2014 Aug;140(8):698-703

Authors: Jahanshahi J, Pazira S, Farahani F, Hashemian F, Shokri N, Karkhanei B, Poorolajal J

IMPORTANCE: Postoperative sore throat is one of the most common problems after tonsillectomy. Antibiotics remove the local flora and reduce inflammation and thus may reduce postoperative pain after tonsillectomy.
OBJECTIVE: To assess the effect of topical sucralfate and clindamycin on local pain reduction after tonsillectomy in children aged 6 to 12 years.
DESIGN, SETTING, AND PARTICIPANTS: Triple-blind randomized clinical trial of children aged 6 to 12 years with sleep apnea or snoring due to adenotonsillar hypertrophy and chronic airway obstruction or with chronic infections who were candidates for tonsillectomy at Besat Hospital, Hamadan University of Medical Sciences, from May to October 2013.
INTERVENTIONS: Patients were randomly assigned to receive sucralfate mouthwash, clindamycin mouthwash, or placebo (cellulose). The oral cavity was washed before and immediately after surgery with 10 mL of the prepared solution for 1 minute and then suctioned. Then, 8 hours after surgery, the patients were asked to keep 10 mL of the prepared mouthwash solution in their mouths for 1 minute 3 times a day for 3 days.
MAIN OUTCOMES AND MEASURES: Postoperative sore throat evaluated daily for 5 days using the Faces Pain Scale-Revised.
RESULTS: Of 110 patients enrolled, 101 patients remained for analysis. Patients in the placebo group had significantly higher mean (SD) throat pain scores than did patients in both drug groups on postsurgery days 1 through 4. Day 1 scores were 8.00 (1.84) for placebo and 6.00 (1.84) for sucralfate and 6.79 (1.87) for clindamycin (P = .001). Pain scores were not significantly different on day 5. Acetaminophen use was more common in the placebo group on days 3 and 4 (2.97 and 2.44) vs the sucralfate group (2.24 and 2.15) and the clindamycin group (2.36 and 2.12) (P = .001 and .02, respectively). Bleeding on day 1 was more common in the placebo group (3 of 34) vs none in the drug groups. Food intolerance on day 1 was less common in patients receiving sucralfate (2 of 34) than placebo (9 of 34) or clindamycin (11 of 33) (P = .02). There was no significant difference among the 3 groups in numbers of episodes of nocturnal waking, halitosis, earache, nausea, and vomiting.
CONCLUSIONS AND RELEVANCE: This trial indicated that topical sucralfate and clindamycin are safe drugs with no important adverse effects that can significantly reduce posttonsillectomy pain in children and help them return to normal life sooner.
TRIAL REGISTRATION: Iranian Registry of Clinical Trials registration number: IRCT201303209014N16.

PMID: 24946226 [PubMed - indexed for MEDLINE]


Join IPSA. It's free!!!   
Just add Your data to the membership module  

Upcoming Meetings   


Home|IPSA Mission|Board|Bylaws|Contact IPSA|Membership|Site Map
Copyright (c) 2014 IPSA Terms Of Use Privacy Statement